转移性结直肠癌各治疗线患者特征与预后因素:Aide et Recherche en Cancérologie Digestive 数据库分析
基于48项随机试验的37,560例转移性结直肠癌患者个体数据,分析各治疗线患者/肿瘤特征演变及预后影响,建立总预后评分(OPS)。七项常规变量构成的模型在1L、2L、3L分别定义四个预后显著不同的亚组,C指数在构建集为0.65、0.66、0.69,验证集为0.65、0.66、0.68。OPS不具预测性,各预后组中3L药物(对比安慰剂)或后续治疗线均延长生存。
要点
- OPS由ECOG体力状态、血红蛋白、血小板计数、WBC/中性粒细胞绝对值比值、LDH、ALP及转移部位数七项变量构成。
- OPS在1L、2L、3L分别定义四个预后显著不同的亚组,C指数构建集0.65、0.66、0.69,验证集0.65、0.66、0.68。
- OPS不具预测性,各预后组中3L药物(对比安慰剂)或后续治疗线均延长生存。
核心结论
- 使用常规变量建立的同一预后模型可用于所有治疗线之前,OPS或可更好地区分未来临床试验患者并辅助常规实践中的治疗决策。
研究设计与样本
- 分析48项随机试验的个体患者数据,共37,560例(1L 26,974例、2L 7,693例、3L 2,893例),终点为总生存(从随机分组至死亡),缺失数据经填补。
- 完整数据集分为构建集(80%)与验证集(20%),采用Cox模型定义OPS风险组,通过自举法获得乐观校正的校准与区分C指数,并在验证集进行内部验证。
主要发现
- 纳入治疗试验的患者/肿瘤部分临床、生物学及分子特征随治疗线演变。
- 最终多变量模型保留七项各线共有的独立预后变量:ECOG体力状态、血红蛋白、血小板计数、WBC/中性粒细胞绝对值比值、乳酸脱氢酶、碱性磷酸酶及转移部位数。
- OPS在1L、2L、3L分别定义四个预后显著不同的亚组,构建集C指数分别为0.65、0.66、0.69,验证集分别为0.65、0.66、0.68。
- OPS不具预测性,3L药物(对比安慰剂)或后续治疗线(2L/1L或3L/2L)在所有预后组中均延长生存。
临床怎么用
- 作者认为,使用常规变量的同一预后模型可用于所有治疗线之前。
- 作者认为,OPS或可更好地区分未来临床试验患者并辅助常规实践中的治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Several lines of treatment can be used sequentially in patients with metastatic colorectal cancer. We investigated the evolution of patient/tumor characteristics and their prognostic impact across treatment lines to develop an overall prognostic score (OPS). PATIENTS AND METHODS: Individual patient data from 48 randomized trials were analyzed. The end point was overall survival (from random assignment to death). Missing data were imputed. The complete data set was then separated into construction (80%) and validation sets (20%). The Cox's model was used to define risk groups for survival using the OPS. The discrimination capability was assessed in each treatment-line via bootstrapping to obtain optimism-corrected calibration and discrimination C-indices. Internal validation was done in the validation set. RESULTS: A total of 37,560 patients (26,974 in first-line [1L], 7,693 in second-line [2L], and 2,893 in third-line [3L]) were analyzed. Some clinical, biological, and molecular characteristics of patients/tumors included in therapeutic trials evolve over the lines. Seven independent prognostic variables were retained in the final multivariate model common to all lines: Eastern Cooperative Oncology Group performance status, hemoglobin, platelet count, WBC/absolute neutrophil count ratio, lactate dehydrogenase, alkaline phosphatase, and the number of metastatic sites. The OPS was used to define four patient subgroups with significantly different prognoses in 1L, 2L, and 3L, separately, with adequate C-indices: 0.65, 0.66, and 0.69 in the construction set and 0.65, 0.66, and 0.68 in the validation set, respectively. The OPS was not predictive, with 3L drugs (v placebo) or subsequent line (2L/1L or 3L/2L) extending survival in all prognostic groups. CONCLUSION: The same prognostic model using practical variables can be used before all treatment lines. The OPS could better stratify patients in future clinical trials and help to therapeutic decision in routine practice.
引用
- Bachet JB, de Gramont A, Raeisi M, et al. Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database. J Clin Oncol. 2025. PMID: 40324123. doi:10.1200/JCO-24-01968
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。